araag2/HINT huggingface dataset:
Clinical trial NCT00265382 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ziprasidone oral capsules
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Reason stopped: 
    please see detailed description for termination reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participation in double-blind treatment study A1281134, meeting specific criteria of
             duration and safety

        Exclusion Criteria:

          -  Imminent risk of suicide or homicide, as judged by the site investigator

          -  Serious adverse event related to study medication in study A1281134

          -  Significant prolongation of QT interval in study A1281134
Clinical trial NCT00332059 (phase 3, status: completed)
Conditions: ocular hypertension
ICD codes: H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost/timolol fixed combination
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of glaucoma or ocular hypertension in both eyes

          -  Patient requires IOP-lowering drug in both eyes

        Exclusion Criteria:

          -  Uncontrolled medical conditions

          -  Contraindication to beta-adrenoceptor antagonist therapy
Clinical trial NCT00391872 (phase 3, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: ticagrelor, clopidogrel
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female 18 years or older who has been hospitalised for chest pain and
             potential ACS

          -  Females of child-bearing potential must have a negative pregnancy test at enrollment
             and be willing to use 2 methods of reliable contraception

        Exclusion Criteria:

          -  Persons with moderate or severe liver disease

          -  Persons who have already been treated with an invasive (angioplasty) procedure for the
             current episode of ACS

          -  Persons who are being treated with blood clotting agents that cannot be stopped
Clinical trial NCT00422123 (phase 3, status: completed)
Conditions: affective psychosis, bipolar, manic disorder, manic-depressive psychosis, mania, manic state, psychoses, manic-depressive
ICD codes: F31.10, F31.11, F31.12, F31.13, F31.2, F31.73, F31.74
Drugs: quetiapine fumarate (seroquel) sr
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Documented diagnosis of Bipolar Disorder, with most recent episode being manic or
             mixed

          -  Inpatient hospital admission for the first 4 days of study treatment

        Exclusion Criteria:

          -  >8 mood episodes within the last 12 months

          -  Use of prohibited medication

          -  Substance or alcohol abuse or dependence

          -  Current suicide risk or suicide attempt within last 6 months.
Clinical trial NCT00282997 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for
             at least 3 months, and pain in at least 11 of 18 specific tender point sites.

          -  Patients must complete the double-blind study.

        Exclusion Criteria:

          -  Patients who experienced a serious adverse event during the previous fibromyalgia
             study, which was determined to be related to the study medication.
Clinical trial NCT01111383 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tobramycin
SMILES: CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  Successful completion of Core Study

          -  At least 6 years of age

          -  Males and females
Clinical trial NCT00070655 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: sr34006 (idraparinux sodium) injection, vitamin k antagonist (warfarin or acenocoumarol) tablets
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  ECG-documented atrial fibrillation (AF) and an indication for long-term vitamin K
             antagonist (VKA) therapy based on the presence of at least one of the following risk
             factors:

               1. previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism

               2. hypertension requiring drug treatment

               3. left ventricular dysfunction (left ventricular ejection fraction <45% or
                  symptomatic congestive heart failure)

               4. age >75 years

               5. age between 65-75 years plus diabetes mellitus, or

               6. age between 65-75 years plus symptomatic coronary artery disease (previous
                  myocardial infarction (MI) or angina pectoris)

          -  Written informed consent

        Exclusion Criteria:

          -  Legal lower age limitations (country specific)

          -  Indication for VKA other than AF, including prosthetic heart valves, venous
             thromboembolism, and planned cardioversion

          -  Transient AF caused by a reversible disorder

          -  Active bleeding or high risk of bleeding

          -  Recent (<15 days) or anticipated invasive procedures with potential for uncontrolled
             bleeding, including major surgery

          -  Participation in another pharmacotherapeutic study within the prior 30 days

          -  Creatinine clearance <10 mL/min, severe hepatic disease, or bacterial endocarditis

          -  Uncontrolled hypertension: systolic blood pressure > 180 mm Hg and/or diastolic blood
             pressure > 110 mm Hg

          -  Pregnancy or childbearing potential without proper contraceptive measures

          -  Breastfeeding

          -  Any other contraindication listed in the labeling of warfarin or acenocoumarol
Clinical trial NCT00699998 (phase 3, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: clopidogrel, prasugrel, commercially-available aspirin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have had a Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) index
             event within 10 days prior to randomization

          -  Had a medical management strategy decision made with reasonable certainty that neither
             percutaneous coronary intervention (PCI) nor coronary artery bypass graft (CABG) is
             planned for treatment of the index event

          -  Had at least 1 of 4 specified high-risk features at the time of the UA/NSTEMI event

        Key Exclusion Criteria:

          -  Decision for medical management greater than 72 hours after onset of index event
             without commercial clopidogrel treatment within 72 hours following onset of the index
             event.

          -  Insignificant coronary artery disease (CAD) on coronary angiography if performed for
             Index Event (absence of greater than or equal to 30% stenosis in at least one native
             vessel)

          -  Previous or planned PCI or CABG as treatment for the index event

          -  PCI/CABG within previous 30 days

          -  ST-segment elevation myocardial infarction (STEMI) as the index event

          -  Cardiogenic shock, Refractory ventricular arrhythmias, New York Heart Association
             (NYHA) Class IV congestive heart failure (CHF) within the previous 24 hours

          -  History of ischemic or hemorrhagic stroke, transient ischemic attack (TIA),
             Intracranial neoplasm, arteriovenous malformation, or aneurysm

          -  History of spontaneous gastrointestinal (GI) or non-GI bleeding requiring
             hospitalization for treatment, unless definitive treatment has occurred and there is
             low likelihood of recurrence

          -  Hemodialysis or peritoneal dialysis
Clinical trial NCT01309841 (phase 3, status: completed)
Conditions: opioid-induced constipation (oic)
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: nktr-118, nktr-118, placebo
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent prior to any study-specific procedures.

          -  Men and women who are between the ages of ≥18 and <85 years.

          -  Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing ≥1
             reported symptom of hard/lumpy stools, straining, or sensation of incomplete
             evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks);
             and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation
             period.

          -  Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30
             mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid
             therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with
             no anticipated change in opioid dose requirement over the proposed study period as a
             result of disease progression.

          -  Willingness to stop all laxatives and other bowel regimens including prune juice and
             herbal products throughout the 2-week OIC confirmation period and the 12-week
             treatment period, and to use only bisacodyl as rescue medication if a BM has not
             occurred within at least 72 hours of the last recorded BM.

        Exclusion Criteria:

          -  Patients receiving Opioid regimen for treatment of pain related to cancer.

          -  History of cancer within 5 years from first study visit with the exception of basal
             cell cancer and squamous cell skin cancer.

          -  Medical conditions and treatments associated with diarrhea, intermittent loose stools,
             or constipation.

          -  Other issues to the gastrointestinal tract that could impose a risk to the patient.

          -  Pregnancy or lactation.
Clinical trial NCT01715415 (phase 3, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450/r/abt-267, abt-333, ribavirin, placebo for abt-450/r/abt-267, placebo for abt-333, placebo for ribavirin
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females must be post-menopausal for at least 2 years or surgically sterile or
             practicing specific forms of birth control.

          -  Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL
             at screening.

          -  Previous treatment failure of peg-interferon and ribavirin (pegIFN and RBV).

          -  No evidence of liver cirrhosis.

        Exclusion Criteria:

          -  Positive screen for drugs or alcohol.

          -  Significant sensitivity to any drug.

          -  Use of contraindicated medications within 2 weeks of dosing.

          -  Certain predefined abnormal laboratory tests.

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody.
Clinical trial NCT01113541 (phase 3, status: terminated)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: ziprasidone hcl (oral)
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must present at least 2 of the following risk factors of MS at screening:
             Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated
             triglycerides (TGs): ≥1.7 mmol/L (≥150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L
             (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: ≥
             5.6 mmol/L.

          -  According to the clinical judgment of the investigator, the risk factors for MS have
             developed in close temporal relationship to starting an antipsychotic medication.

          -  Substitution to a less metabolically disruptive antipsychotic medication is considered

        Exclusion Criteria:

          -  Subjects with contraindication(s) to the use of Ziprasidone according to Canadian
             prescribing information.

          -  Subjects with a history of treatment resistance.

          -  Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing
             dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate
             or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that
             may confound the evaluation of the study drug.

          -  Body mass index ≥ 40 at baseline.
Clinical trial NCT01191762 (phase 3, status: completed)
Conditions: hyperparathyroidism, chronic kidney disease
ICD codes: E21.0, E21.2, E21.3, E21.1, N25.81, I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: sevelamer carbonate, placebo
SMILES: NCC=C.ClCC1CO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  eGFR < 60 ml/min

          -  age at least 18 years

        Exclusion Criteria:

          -  any primary parathyroid disease
Clinical trial NCT01326026 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation
             (Visit 2)

          -  Current treatment: metformin monotherapy or metformin in any combination with 1 or 2
             other OADs including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl
             peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones
             (TZDs) all with unchanged dosing for at least 12 weeks prior to randomisation (Visit
             2)-metformin: alone or in combination (including fixed combination) must be at least
             1000 mg daily

          -  HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis

          -  BMI (Body Mass Index) no higher than 45.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with glucagon-like peptide 1 (GLP-1) receptor agonist within the last 12
             weeks prior to Visit 2

          -  Suffer from a life threatening disease (e.g. cancer)

          -  Females of childbearing potential who are pregnant (as determined by central
             laboratory beta-human chorionic gonadotropin (beta-hCG), breast feeding or intend to
             become pregnant or are not using adequate contraceptive methods (adequate
             contraceptive methods as required by law or practise [for Germany, adequate
             contraceptive methods are: implants, injectables, combined oral contraceptives,
             hormonal IUD, sexual abstinence or vasectomised partner])
Clinical trial NCT01154127 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who signed an Informed Consent Form prior to initiation of any study-related
             procedure

          -  Patients with moderate to severe stable COPD (clinical diagnosis in compliance with
             GOLD 2008)

          -  Current or ex-smokers with a smoking history ≥ 10 pack years. (Ten pack-years were
             defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years
             etc.).

          -  Patients with a post-bronchodilator FEV1 ≥ 40 and < 70% of the predicted normal, and
             postbronchodilator FEV1/FVC < 0.7 during screening. (Post referred to the highest
             post-bronchodilator value after inhalation of 80 μg ipratropium bromide)

          -  Increase in FEV1 from pre- to post-bronchodilator assessment of ≥ 5%

        Exclusion Criteria:

          -  Pregnant women or nursing mothers

          -  Women of child-bearing potential

          -  Patients who had a COPD exacerbation (whether hospitalized or not) in the 6 weeks
             prior to Visit 1 or between Visit 1 and Visit 4

          -  Patients who had a lower respiratory tract infection in the 6 weeks prior to Visit 1

          -  Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia

          -  Patients with resting (5 min) oxygen SaO2 (or SpO2) saturation on room air of < 85%

          -  Patients with a maximum workload (Wmax) value < 20 W (as determined by the incremental
             cycle endurance test) at Visit 2.

          -  Patients whose exercise endurance time at sub-maximal workload was above 25 min at
             baseline

          -  Patients with a clinically significant abnormality on the screening or baseline ECG
             who in the judgment of the investigator would have been at potential risk if enrolled
             into the study

          -  Patients with a history of long QT syndrome or whose QTc was prolonged (> 450 ms for
             males and > 470 ms females) at screening (Fredericia's correction)

        Other protocol-defined inclusion/exclusion criteria applied
Clinical trial NCT00613106 (phase 3, status: completed)
Conditions: osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, chronic soft tissue pain
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, G90.50, G90.511, G90.512, G90.513, G90.519, G90.521, G90.522
Drugs: hzt-501, ibuprofen
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Expected to continue to require daily administration of an NSAID for at least the
             coming 6 months.

          -  Subject completed the 24-week Treatment period of either Horizon Protocol HZ-CA-301 or
             HZ-CA-303

        Exclusion Criteria:

          -  Subject didn't meet all of the Inclusion and Exclusion Criteria for Horizon Protocol
             HZ-CA-301 or HZ-CA-303

          -  Subject developed or experienced any of the following while on either HZ-CA-301 or
             HZ-CA-303

          -  Malignant Disease of the gastrointestinal tract

          -  Erosive esophagitis

          -  Clinically significant cardiac, renal or hepatic disease

          -  Uncontrolled diabetes

          -  Positive pregnancy test on Study Day 0

          -  Please note that there are other additional criteria. The study center will determine
             if you meet all of the criteria.
Clinical trial NCT01227889 (phase 3, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gsk2118436, dacarbazine (dtic)
SMILES: CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults at least 18 years of age

          -  Has advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF
             mutation positive (V600E)

          -  Is treatment naive for advanced (unresectable) or metastatic melanoma, with the
             exception of Interleukin 2 (IL-2) which is allowed.

          -  Has measurable disease according to RECIST 1.1 criteria.

          -  Women of child-bearing potential must have a negative pregnancy test within 14 days
             prior to the first dose of study treatment.

          -  Women with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 4 weeks after the last dose of study
             medication.

          -  Men with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 16 weeks after the last dose of study
             medication.

          -  Must have adequate organ function.

          -  Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

        Exclusion Criteria:

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy,
             biologic therapy or surgery).

          -  Evidence of active central nervous system (CNS) disease.

          -  Previous treatment for metastatic melanoma, including treatment with BRAF or MEK
             inhibitor.

          -  A history of other malignancy. Subjects who have been disease-free for 5 years or
             subjects with a history of complete resected non-melanoma skin cancer or successfully
             treated in situ carcinoma are eligible.

          -  History of Human Immunodeficiency Virus (HIV) infection.

          -  Certain cardiac abnormalities